Rotavirus genotype distribution in Kyrgyzstan and Kazakhstan, 2007-2009.
This is the first study to present rotavirus genotype distribution in children admitted to a hospital with acute gastroenteritis in Kyrgyzstan and Kazakhstan from January 2007 through December 2009. In total, 858 rotavirus ELISA-positive samples were characterized by RT-PCR, with a considerable geographical and seasonal variation in genotype distribution observed during the study. The globally common genotypes (G1P[8], G2P[4], G3P[8], G4P[8], G9P[8], G12P[8] and G12P[6]) accounted for 81.5-88.2% of the infections in Kyrgyzstan and 72.3-79.3% of the infections in Kazakhstan. The predominant genotypes were G1P[8], G2P[4] and G3P[8]. G1P[8] was the dominating genotype in Kyrgyzstan, detected in 51-64.7% of the samples. A similar predominance was not seen for G1P[8] in Kazakhstan, with a shift to G2P[4] predominance being seen in 2008. G9P[8] was a rare genotype in both countries, whereas G12 was detected in between 2.2% and 7.6% of the samples. The surveillance period was characterized by many co-circulating genotypes, and eight unusual combinations (G1P[4], G2P[8], G2P[6], G3P[4], G9P[4], G12P[4], G9P[9] and G10P[4]) were detected. This study provides important baseline data on rotavirus genotypes in Kyrgyzstan and Kazakhstan in the pre-vaccine era, and the results may indicate that the two licensed vaccines can be expected to prevent rotavirus disease in these countries.
Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway. kirsti.vainio@fhi.no
Kirsti
K
Vainio
Renat
R
Latipov
Elmira
E
Utegenova
Kaliya
K
Kasymbekova
Rivojiddin
R
Juraev
Mukhayyo
M
Asilova
Elmira
E
Flem
D000208:Acute Disease; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D062665:Epidemiological Monitoring; D005243:Feces / Q000821:virology; D005759:Gastroenteritis / Q000453:epidemiology* / Q000821:virology; D005838:Genotype; D006801:Humans; D007623:Kazakhstan / Q000453:epidemiology; D007707:Kyrgyzstan / Q000453:epidemiology; D015995:Prevalence; D011446:Prospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012401:Rotavirus / Q000235:genetics* / Q000302:isolation & purification* / Q000472:pathogenicity; D012400:Rotavirus Infections / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology; D022243:Rotavirus Vaccines / Q000627:therapeutic use
D022243:Rotavirus Vaccines